Login to MyKarger

New to MyKarger? Click here to sign up.

Login with Facebook

Forgot Password? Reset your password

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login (Shibboleth)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Table of Contents
Vol. 33, No. 4, 2010
Issue release date: August 2010
Section title: Original Paper
Kidney Blood Press Res 2010;33:304–312

Effects of Telmisartan on Arterial Stiffness Assessed by the Cardio-Ankle Vascular Index in Hypertensive Patients

Kinouchi K.a · Ichihara A.b · Sakoda M.a · Kurauchi-Mito A.a · Murohashi-Bokuda K.a · Itoh H.a
Departments of aEndocrinology, Metabolism, and Nephrology, and bEndocrinology and Anti-Aging Medicine and Internal Medicine, Keio University School of Medicine, Tokyo, Japan
email Corresponding Author

Atsuhiro Ichihara, MD, PhD, FAHA

Endocrinology and Anti-Aging Medicine, Keio University School of Medicine

35 Shinanomachi, Shinjuku-ku

Tokyo 160-8582 (Japan)

Tel. +81 3 5363 3796, Fax +81 3 3359 2745, E-Mail atzichi@sc.itc.keio.ac.jp


  1. Laurent S, Boutouyrie P, Asmar R, Gautier I, Laloux B, Guize L, Ducimetiere P, Benetos A: Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension 2001;37:1236–1241.
  2. Mitchell G: Effects of central arterial aging on the structure and function of the peripheral vasculature: implications for end-organ damage. J Appl Physiol 2008;105:1652–1660.
  3. Safar M: Systolic blood pressure, pulse pressure and arterial stiffness as cardiovascular risk factors. Curr Opin Nephrol Hypertens 2001;10:257–261.
  4. Williams B, Lacy P, Thom S, Cruickshank K, Stanton A, Collier D, Hughes A, Thurston H, O’Rourke M, CAFE Investigators; Anglo-Scandinavian Cardiac Outcomes Trial Investigators; CAFE Steering Committee and Writing Committee: Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006;113:1213–1225.
  5. Ichihara A, Yamashita N, Takemitsu T, Kaneshiro Y, Sakoda M, Kurauchi-Mito A, Itoh H: Cardio-ankle vascular index and ankle pulse wave velocity as a marker of arterial fibrosis in kidney failure treated by hemodialysis. Am J Kidney Dis 2008;57:947–955.
    External Resources
  6. Okura T, Watanabe S, Kurata M, Manabe S, Koresawa M, Irita J, Enomoto D, Miyoshi K, Fukuoka T, Higaki J: Relationship between cardio-ankle vascular index (CAVI) and carotid atherosclerosis in patients with essential hypertension. Hypertension Res 2007;30:335–340.
  7. Mahmud A, Feely J: Effect of angiotensin II receptor blockade on arterial stiffness: beyond blood pressure reduction. Am J Hypertens 2002;15:1092–1095.
  8. Benson S, Pershadsingh H, Ho C, Chittiboyina A, Desai P, Pravenec M, Qi N, Wang J, Avery M, Kurtz T: Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARγ-modulating activity. Hypertension 2004;43:993–1002.
  9. Uchida H, Nakamura Y, Kaihara M, Sugimoto T, Norii H, Sasaki M, Sato H, Makino H: Practical efficacy of telmisartan for decreasing morning home blood pressure and pulse wave velocity in patients with mild-to-moderate hypertension. Hypertension Res 2004;27:545–550.
  10. Pontremoli R, Leoncini G, Viazzi F, Ratto E, Vaccaro V, Falqui V, Parodi A, Conti N, Tomolillo C, Deferrari G: Evaluation of subclinical organ damage for risk assessment and treatment in the hypertensive patient: role of microalbuminuria. J Am Soc Nephrol 2006;17(4 Suppl 2):S112–S114.
    External Resources
  11. Ichihara A, Kaneshiro Y, Takemitsu T, Sakoda M: Effects of amlodipine and valsartan on vascular damage and ambulatory blood pressure in untreated hypertensive patients. J Hum Hypertens 2006;10:787–794.
    External Resources
  12. Kinouchi K, Ichihara A, Sakoda M, Kurauchi-Mito A, Itoh H: Safety and benefits of a tablet combining losartan and hydrochlorothiazide in Japanese diabetic patients with hypertension. Hypertension Res 2009;32:1143–1147.
  13. Sakuragi S, Maruo T, Taniguchi M, Nagase S, Nakamura K, Kusano K, Ohe T: Radial augmentation index associated with increase in b-type natriuretic peptide in patients with hypertension. Int J Cardiol 2008;130:414–419.
  14. Morimoto S, Yano Y, Maki K, Sawada K: Renal and vascular protective effects of telmisartan in patients with essential hypertension. Hypertension Res 2006;29:567–572.
  15. Duan S, Usher M, Mortensen R: Peroxisome proliferator-activated receptor-mediated effects in the vasculature. Circ Res 2008;102:283–294.
  16. Willum-Hansen T, Staessen J, Torp-Pedersen C, Rasmussen S, Thijs L, Ibsen H, Jeppesen J: Prognostic value of aortic pulse wave velocity as index of arterial stiffness in the general population. Circulation 2006;113:664–670.
  17. Dawson A, Davies J, Morris A, Struthers A: B-type natriuretic peptide is associated with both augmentation index and left ventricular mass in diabetic patients without heart failure. Am J Hypertens 2005;18:1586–1591.
  18. Asmar R, Gosse P, Topouchian J, N’tela G, Dudley A, Shepherd G: Effects of telmisartan on arterial stiffness in type 2 diabetes patients with essential hypertension. J Renin Angiotensin Aldosterone Syst 2002;3:176–180.
  19. Grassi G, Quarti-Trevano F, Mancia G: Review: cardioprotective effects of telmisartan in uncomplicated and complicated hypertension. J Renin Angiotensin Aldosterone Syst 2008;9:66–74.
  20. Symeonides P, Koulouris S, Vratsista E, Triantafyllou K, Ioannidis G, Thalassinos N, Katritsis D: Both ramipril and telmisartan reverse indices of early diabetic cardiomyopathy: a comparative study. Eur J Echocardiogr 2006;8:480–486.
  21. Petrovic I, Petrovic D, Vukovic N, Zivanovic B, Dragicevic J, Vasiljevic Z, Babic R: Ventricular and vascular remodelling effects of the angiotensin II receptor blocker telmisartan and/or the angiotensin-converting enzyme inhibitor ramipril in hypertensive patients. J Int Med Res 2005;33:39A–49A.
  22. Garg J, Bakris G: Microalbuminuria: marker of vascular dysfunction, risk factor for cardiovascular disease. Vasc Med 2002;7:35–43.
  23. Gerstein H, Mann J, Yi Q, Zinman B, Dinneen S, Hoogwerf B, Halle J, Young J, Rashkow A, Joyce C, Nawaz S, Yusuf S: Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001;286:421–426.
  24. Parving H, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P; Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:870–878.
  25. Viberti G, Wheeldon N; MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators: Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 2002;106:672–678.
  26. Bichu P, Nistala R, Khan A, Sowers J, Whaley-Connell A: Angiotensin receptor blockers for the reduction of proteinuria in diabetic patients with overt nephropathy: results from the AMADEO study. Vasc Health Risk Manag 2009;5:129–140.
  27. Yano Y, Hoshide S, Ishikawa J, Noguchi C, Tukui D, Takanori H, Tada M, Kanemaru Y, Yano A, Ishikawa S, Shimada K, Kario K: The differential effects of angiotensin II type 1 receptor blockers on microalbuminuria in relation to low-grade inflammation in metabolic hypertensive patients. Am J Hypertens 2007;20:565–572.
  28. Masuda S, Tamura K, Wakui H, Kanaoka T, Ohsawa M, Maeda A, Dejima T, Yanagi M, Azuma K, Umemura S: Effects of angiotensin II type 1 receptor blocker on ambulatory blood pressure variability in hypertensive patients with overt diabetic nephropathy. Hypertension Res 2009;32:950–955.
  29. Nakamoto H, Nishida E, Ryuzaki M, Sone M, Suzuki H, Yoshimoto M, Itagaki K: Effect of telmisartan and amlodipine on home blood pressure by monitoring newly developed telemedicine system: monitoring test by using telemedicine. Telmisartan’s effect on home blood pressure (TelTelbosu). Clin Exp Hypertens 2008;30:57–67.
  30. Mancia G, Grassi G: Mechanisms and clinical implications of blood pressure variablity. J Cardiovasc Pharmacol 2000;35:S15–S19.
  31. Mancia G, Bombelli M, Facchetti R, et al: Long-term prognostic value of blood pressure variability in the general population: results of the Pressioni Arteriose Monitorate e Loro Associazioni Study. Hypertension 2007;49:1265–1270.
  32. Kyvelou S, Vyssoulis G, Karpanou E, Adamopoulos D, Zervoudaki A, Pietri P, Stefanadis C: Effects of antihypertensive treatment with angiotensin II receptor blockers on lipid profile: an open multi-drug comparison trial. Hellenic J Cardiol 2006;47:21–28.
    External Resources
  33. Derosa G, Ragonesi P, Mugellini A, Ciccarelli L, Fogari R: Effects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism and lipid profile in hypertensive, type 2 diabetic patients: a randomized, double-blind, placebo-controlled 12-month study. Hypertension Res 2004;27:457–464.
  34. ONTARGET Investigators; Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C: Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547–1559.
  35. Ogihara T, Nakao K, Fukui T, Fukiyama K, Ueshima K, Oba K, Sato T, Saruta T: Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: candesartan antihypertensive survival evaluation in Japan trial. Hypertension 2008;51:393–398.